Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

Tucidinostat (formerly known as chidamide) is an orally available, novel benzamide class of histone deacetylase (HDAC) inhibitor that selectively blocks class I and class IIb HDAC. This multicenter phase IIb study aimed to investigate the efficacy and safety of tucidinostat, 40 mg twice per week (BI...

Descripción completa

Detalles Bibliográficos
Autores principales: Rai, Shinya, Kim, Won Seog, Ando, Kiyoshi, Choi, Ilseung, Izutsu, Koji, Tsukamoto, Norifumi, Yokoyama, Masahiro, Tsukasaki, Kunihiro, Kuroda, Junya, Ando, Jun, Hidaka, Michihiro, Koh, Youngil, Shibayama, Hirohiko, Uchida, Toshiki, Yang, Deok Hwan, Ishitsuka, Kenji, Ishizawa, Kenichi, Kim, Jin Seok, Lee, Hong Ghi, Minami, Hironobu, Eom, Hyeon Seok, Kurosawa, Mitsutoshi, Lee, Jae Hoon, Lee, Jong Seok, Lee, Won Sik, Nagai, Hirokazu, Shindo, Takero, Yoon, Dok Hyun, Yoshida, Shinichiro, Gillings, Mireille, Onogi, Hiroshi, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Non-Hodgkin Lymphoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973490/
https://www.ncbi.nlm.nih.gov/pubmed/36200417
http://dx.doi.org/10.3324/haematol.2022.280996

Ejemplares similares

Ejemplares similares